-
公开(公告)号:US20240002364A1
公开(公告)日:2024-01-04
申请号:US18461093
申请日:2023-09-05
Applicant: BRISTOL-MYERS SQUIBB COMPANY
Inventor: CHUNJIAN LIU , MICHAEL G. YANG , ZILI XIAO , LING CHEN , RYAN M. MOSLIN , JOHN S. TOKARSKI , DAVID S. WEINSTEIN , STEPHEN T. WROBLESKI
IPC: C07D401/14 , C07D401/12 , C07D413/14 , C07D471/04 , C07D405/14 , C07F9/6558 , C07D417/14 , A61P37/00 , A61P29/00 , A61K31/501 , C07D487/04
CPC classification number: C07D401/14 , C07D401/12 , C07D413/14 , C07D471/04 , C07D405/14 , C07F9/65583 , C07D417/14 , A61P37/00 , A61P29/00 , A61K31/501 , C07D487/04
Abstract: Compounds having the following formula I:
or a stereoisomer or pharmaceutically-acceptable salt thereof, where R1, R2, R3, R4, and R5 are as defined herein, are useful in the modulation of IL-12, IL-23 and/or IFNα, by acting on Tyk-2 to cause signal transduction inhibition.-
公开(公告)号:US20250066322A1
公开(公告)日:2025-02-27
申请号:US18560520
申请日:2022-05-13
Applicant: BRISTOL-MYERS SQUIBB COMPANY
Inventor: MICHAEL EDWARD MERTZMAN , RYAN M. MOSLIN , STEVEN H. SPERGEL , KARIN IRMGARD WORM
IPC: C07D401/12 , A61K31/444 , A61K31/501
Abstract: There are disclosed compounds of the following formula (I): or a stereoisomer or pharmaceutically acceptable salt thereof, wherein all substituents are as defined herein, which are useful in the modulation of IL-12, IL-23 and/or IFNα, by acting on Tyk-2 to cause signal transduction inhibition. The compounds of the invention may be useful for treating neurodegenerative diseases or disorders.
-
公开(公告)号:US20240317718A1
公开(公告)日:2024-09-26
申请号:US18560485
申请日:2022-05-13
Applicant: BRISTOL-MYERS SQUIBB COMPANY
Inventor: STEVEN H. SPERGEL , RYAN M. MOSLIN , MICHAEL EDWARD MERTZMAN , SHOSHANA L. POSY , SIRISH KAUSHIK LAKKARAJU , JOSEPH A. TINO , ZILI XIAO , CHUNJIAN LIU , JAMES LIN
IPC: C07D403/12 , A61K31/501 , A61K31/506 , C07D401/12 , C07D401/14 , C07D413/12 , C07D417/12 , C07D417/14
CPC classification number: C07D403/12 , A61K31/501 , A61K31/506 , C07D401/12 , C07D401/14 , C07D413/12 , C07D417/12 , C07D417/14
Abstract: There are disclosed compounds of the following formula (I) or a stereoisomer or pharmaceutically acceptable salt thereof, wherein all substituents are as defined herein, which are useful in the modulation of IL-12, IL-23 and/or IFNα, by acting on Tyk-2 to cause signal transduction inhibition. The compounds of the invention may be useful for treating neurodegenerative diseases or disorders.
-
-